Cogent Biosciences, Inc. — Q2 2021 Form 10-Q
Reporting period: Three and six months ended June 30, 2021. Cogent is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases. Its lead candidate, bezuclastinib (CGT9486), targets KIT mutations implicated in systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST). The company had no approved products and no product-sales revenue.
Financial performance and liquidity
| Metric | Q2 2021 | Six months 2021 |
|---|---|---|
| Collaboration revenue | $0 | $0 |
| Research and development expense | $12.4 million | $20.6 million |
| General and administrative expense | $4.9 million | $9.5 million |
| Net loss | $16.5 million | $28.3 million |
| Net loss per share, basic and diluted | $0.43 | $0.77 |
| Operating cash used | Not separately stated | $23.9 million |
At June 30, cash and cash equivalents were $218.1 million, down from $242.2 million at year-end 2020; cash, cash equivalents and restricted cash totaled $219.4 million. Current assets were $221.4 million and current liabilities were $13.7 million. Total liabilities were $15.7 million, principally including lease liabilities and the contingent value right (CVR); the filing reports no conventional borrowings. Accumulated deficit was $227.0 million. The company said its cash should fund operations and capital requirements into 2024; the financial-statement note separately states it expects resources to cover at least 12 months from issuance.
No product gross margin is applicable because Cogent had no product sales. Six-month investing cash use was $0.1 million, and financing cash use was $0.1 million, mainly for partial CVR settlement. The company has a $200 million shelf registration and an at-the-market sales agreement of up to $75 million; no ATM shares had been sold by June 30.
Changes versus prior comparable periods
- Q2 net loss increased to $16.5 million from $7.4 million; six-month net loss increased to $28.3 million from $13.5 million.
- R&D expense rose to $12.4 million from $5.1 million for Q2 and to $20.6 million from $14.6 million for six months, reflecting bezuclastinib development and higher headcount.
- G&A expense rose to $4.9 million from $2.8 million for Q2 and to $9.5 million from $6.5 million for six months, primarily due to increased headcount and related costs.
- Prior-year collaboration revenue—$0.5 million for Q2 and $7.6 million for six months—related to legacy assets; all performance obligations were completed and no comparable revenue was recorded in 2021.
- Common shares outstanding increased to 39.8 million from 32.3 million at December 31, 2020, including conversions of preferred stock. Potential common shares from options and convertible preferred stock were excluded from diluted loss per share as anti-dilutive.
Outlook, developments and risks
- The Phase 2 APEX trial in advanced SM began in Q2; preliminary data were expected in the first half of 2022. Cogent expected to start the SUMMIT trial in non-advanced SM in the second half of 2021.
- For bezuclastinib plus sunitinib in a small group of 15 heavily pre-treated GIST patients, the company cited a 20% confirmed objective response rate and estimated median progression-free survival of 12 months. A randomized combination trial was expected to begin in the second half of 2021; FDA interaction was planned regarding further GIST development.
- Management expects expenses to increase as clinical and preclinical programs advance. The company expects to need additional funding; equity financing could dilute shareholders, while collaborations or licensing could require relinquishing rights. The cash runway estimate depends on assumptions and could prove shorter than expected.
- COVID-19 had not materially affected the company as of June 30, 2021, but could disrupt trials, research, suppliers, or capital access. The filing identifies clinical, regulatory, manufacturing, competition, intellectual-property, and financing risks; it reports no material change to the risk factors in the 2020 Form 10-K.
- A July 2021 lease for approximately 38,075 square feet of Boulder office and laboratory space has a 12-year initial term, with rent commencing after improvements or by May 1, 2022. The landlord agreed to contribute about $6.9 million to improvements and offered a tenant-improvement loan of up to about $2.3 million at 6% interest.
- The remaining CVR liability was $3.1 million at June 30 and is to be settled in cash. The company reported no material legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Trial enrollment, safety and efficacy results, and timing of APEX, SUMMIT, and the planned GIST study.
- Whether the stated cash runway into 2024 remains achievable as development spending increases, and the assumptions behind that estimate.
- Potential dilution from preferred-stock conversion, equity awards, and future use of the shelf or ATM facility.
- Costs, timing, and financing terms for the Boulder lease and tenant improvements.
- Current CVR settlement obligations, license milestones and royalties, and the effect of ownership-change limits on tax attributes.